REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary
Home > Formulary : Adult > Recent Decisions > 2015 >

Decisions 2nd June 2015

At the meeting that took place on 2nd June, the following decisions were agreed:

 

New Drug Requests

 

Approved

 

Tocilizumab monotherapy (TLS Red)

  • Approved for inclusion onto the formulary for adults with moderate/severe, active rheumatoid arthritis who cannot take methotrexate.

Abatacept subcutaneous (TLS Red)

  • Approved for inclusion onto the formulary for adults with moderate/severe, active rheumatoid arthritis, in combination with methotrexate, in accordance with NICE TAs 195 and 280.

Rituximab in combination with Leflunomide (TLS Red)

  • Approved for inclusion onto the formulary for adults with severe, active rheumatoid arthritis who cannot take methotrexate and who have had inadequate response or intolerance to other DMARDs and one or more anti-TNF therapies.

 

More information required

Simbrinza® (Brinzolamide & Brimonidine)

  • Information regarding current prescribing trends and generic availability required

 

Other decisions

Wound Care Formularies

  • Each organisations version of the PAN AVON Wound care formulary is/will be included on the BNSSG Formulary Website.